Common methodologies for achieving sustained engraftment of full haplotype mismatched HSCT
| Group/Reference . | Number . | Disease . | Method of TCD . | Conditioning . | GVHD prophylaxis . | Comment . |
|---|---|---|---|---|---|---|
| T-replete myeloablative | ||||||
| Beijing; 11 | 250 | 108 AML, 142 ALL | No TCD | G-CSF primed BM and PB, Ara-C, BU, Cy, simustine, ATG | CsA, MMF, MTX | Adult patients |
| Beijing; 99 | 42 | 24 ALL, 12 AML, 6 CML | No TCD | G-CSF primed BM and PB, Ara-C, BU, Cy, simustine, ATG | CsA, MMF, MTX | Pediatric patients |
| T-replete nonmyeloablative | ||||||
| Durham; 50 | 49 | 29 Leuk/MDS, 15 ML/MM, 2 CML, 3 MPD | No TCD | Alemtuzumab, Flu, Cy | MMF ± CsA | Adult patients |
| Toyama; 100 | 66 | 32 high-risk AL, 10 MDS, 19 Ly, 2 CML, 3 MM | No TCD | (2 Gy TBI or Flu) + ATG, BU, Mel | TAC ± mP | Adult patients |
| Baltimore; 101 | 185 | 106 lymphoid malignancy, 78 myeloid malignancies | No TCD | 2 Gy TBI, Cy, Flu | High-dose CY, TAC, MMF | Combined adults and pediatric patients |
| T-deplete myeloablative | ||||||
| Columbia, SC; 102 | 201 | 102 AML, 99 ALL | T10B9 or OKT3 | TBI, Ara-C, Cy, VP-16, ATG, mP | Partial TCD with OKT3 or T10B9 + mP, ATG, CsA | Combined adults and pediatric patients; 51% TRM at 5 years |
| Perugia; 26 | 104 | 67 AML, 37 ALL | CD34+ selection | 8 Gy TBI, Thio, Flu, ATG | None | Combined adults and pediatric patients; all high-risk patients |
| Multi-center; 30 | 266 | 173 AML, 93 ALL | CD34+ selection | TBI-based myeloablation in 74% of AML and 92% of ALL, ATG in majority | NA | All high-risk patients; better LFS for direct family member donor |
| Tubingen; 32 | 63 | 32 ALL, 13 AML/CML, 4 MDS, 4 Ly, 10 NM | CD34+ or CD133+ selection | BU or TBI + ATG/OKT3 + Cy + Thio or Cy + Flu | None | Pediatric patients |
| Bristol; 103 | 34 | 17 AML, 14 ALL, MDS/CML/biphenotypic AL 3 | Campath in the bag (7), CD34+ selection (27) | Cy + 14.4 Gy TBI + IV Campath or ATG | CsA in 7, none in 27 | Pediatric patients |
| Multi-center; 34 | 127 | Very high-risk ALL 102 in CR1-3 25 NR | Mostly CD34+ selection | Myeloablative, TBI in 76% | NA, 96% received ATG or ALG | Multicenter study on pediatric patients; improved LFS in larger centers |
| T-deplete nonmyeloablative | ||||||
| Tubingen; 45 | 29 | 16 AML, 7 ALL, 3 NHL, 2 MM, 1 CML | CD3/CD19 depletion | Flu, Thio, Mel, OKT-3 | None | Adults patients |
| Memphis; 104 | 22 | 9 AML, 9 ALL, 2 CML, 2 Ly | CD3 depletion | Flu, Thio, Mel, OKT-3 | MMF | Pediatric patients |
| Frankfurt; 46 | 59 | 15 ALL, 14 AML, 2 MDS, 13 RMS, 5 solid tumors, 10 NM | CD3/CD19 depletion | Flu, Thio, Mel | NA | Pediatric patients |
| Madrid; 47 | 29 | 18 ALL, 11 AML | CD3/CD19 depletion in 26; CD34+ selection in 3 | Flu, BU, Thio, mP | CsA alone (6) or ATG alone (8) or CsA + MTX (15) | Pediatric patients |
| Group/Reference . | Number . | Disease . | Method of TCD . | Conditioning . | GVHD prophylaxis . | Comment . |
|---|---|---|---|---|---|---|
| T-replete myeloablative | ||||||
| Beijing; 11 | 250 | 108 AML, 142 ALL | No TCD | G-CSF primed BM and PB, Ara-C, BU, Cy, simustine, ATG | CsA, MMF, MTX | Adult patients |
| Beijing; 99 | 42 | 24 ALL, 12 AML, 6 CML | No TCD | G-CSF primed BM and PB, Ara-C, BU, Cy, simustine, ATG | CsA, MMF, MTX | Pediatric patients |
| T-replete nonmyeloablative | ||||||
| Durham; 50 | 49 | 29 Leuk/MDS, 15 ML/MM, 2 CML, 3 MPD | No TCD | Alemtuzumab, Flu, Cy | MMF ± CsA | Adult patients |
| Toyama; 100 | 66 | 32 high-risk AL, 10 MDS, 19 Ly, 2 CML, 3 MM | No TCD | (2 Gy TBI or Flu) + ATG, BU, Mel | TAC ± mP | Adult patients |
| Baltimore; 101 | 185 | 106 lymphoid malignancy, 78 myeloid malignancies | No TCD | 2 Gy TBI, Cy, Flu | High-dose CY, TAC, MMF | Combined adults and pediatric patients |
| T-deplete myeloablative | ||||||
| Columbia, SC; 102 | 201 | 102 AML, 99 ALL | T10B9 or OKT3 | TBI, Ara-C, Cy, VP-16, ATG, mP | Partial TCD with OKT3 or T10B9 + mP, ATG, CsA | Combined adults and pediatric patients; 51% TRM at 5 years |
| Perugia; 26 | 104 | 67 AML, 37 ALL | CD34+ selection | 8 Gy TBI, Thio, Flu, ATG | None | Combined adults and pediatric patients; all high-risk patients |
| Multi-center; 30 | 266 | 173 AML, 93 ALL | CD34+ selection | TBI-based myeloablation in 74% of AML and 92% of ALL, ATG in majority | NA | All high-risk patients; better LFS for direct family member donor |
| Tubingen; 32 | 63 | 32 ALL, 13 AML/CML, 4 MDS, 4 Ly, 10 NM | CD34+ or CD133+ selection | BU or TBI + ATG/OKT3 + Cy + Thio or Cy + Flu | None | Pediatric patients |
| Bristol; 103 | 34 | 17 AML, 14 ALL, MDS/CML/biphenotypic AL 3 | Campath in the bag (7), CD34+ selection (27) | Cy + 14.4 Gy TBI + IV Campath or ATG | CsA in 7, none in 27 | Pediatric patients |
| Multi-center; 34 | 127 | Very high-risk ALL 102 in CR1-3 25 NR | Mostly CD34+ selection | Myeloablative, TBI in 76% | NA, 96% received ATG or ALG | Multicenter study on pediatric patients; improved LFS in larger centers |
| T-deplete nonmyeloablative | ||||||
| Tubingen; 45 | 29 | 16 AML, 7 ALL, 3 NHL, 2 MM, 1 CML | CD3/CD19 depletion | Flu, Thio, Mel, OKT-3 | None | Adults patients |
| Memphis; 104 | 22 | 9 AML, 9 ALL, 2 CML, 2 Ly | CD3 depletion | Flu, Thio, Mel, OKT-3 | MMF | Pediatric patients |
| Frankfurt; 46 | 59 | 15 ALL, 14 AML, 2 MDS, 13 RMS, 5 solid tumors, 10 NM | CD3/CD19 depletion | Flu, Thio, Mel | NA | Pediatric patients |
| Madrid; 47 | 29 | 18 ALL, 11 AML | CD3/CD19 depletion in 26; CD34+ selection in 3 | Flu, BU, Thio, mP | CsA alone (6) or ATG alone (8) or CsA + MTX (15) | Pediatric patients |
CML indicates chronic myelocytic leukemia; Leuk, leukemia; ML, malignant lymphoma; MM, multiple myeloma; AL, acute leukemia; Ly, malignant lymphoma; NM, nonmalignant; NR, not in remission; RMS, rhabdomyosarcoma; NHL, non-Hodgkin lymphoma; TCD, T-cell depletion; Ara-C, cytosine arabinoside; Cy, cyclophosphamide; Flu, fludarabine; BU, busulfan; Mel, melphalan; VP-16, etoposide; mP, methylprednisolone; Thio, thiotepa; CsA, cyclosporine A; MTX, methotrexate; TAC, tacrolimus; and NA, not applicable.